Human Reproduction, Vol. 15, No. 9, 1965-1968,
September 2000
© 2000 European Society of Human Reproduction and Embryology
Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: Short communication
1 Department of Obstetrics and Gynecology, Rambam Medical Center, 2 Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel and 3 NV Organon, Oss, The Netherlands
A new treatment option for patients undergoing ovarian stimulation is the gonadotrophin-releasing hormone (GnRH) antagonist protocol, with the possibility to trigger a mid-cycle LH surge using a single bolus of GnRH agonist, reducing the risk of developing ovarian hyperstimulation syndrome (OHSS) in high responders and the chance of cycle cancellation. This report describes the use of 0.2 mg triptorelin (Decapeptyl®) to trigger ovulation in eight patients who underwent controlled ovarian hyperstimulation with recombinant FSH (rFSH, Puregon®) and concomitant treatment with the GnRH antagonist ganirelix (Orgalutran®) for the prevention of premature LH surges. All patients were considered to have an increased risk for developing OHSS (at least 20 follicles 
11 mm and/or serum oestradiol at least 3000 pg/ml). On the day of triggering the LH surge, the mean number of follicles 11 mm was 25.1 ± 4.5 and the median serum oestradiol concentration was 3675 (range 2980–7670) pg/ml. After GnRH agonist injection, endogenous serum LH and FSH surges were observed with median peak values of 219 and 19 IU/l respectively, measured 4 h after injection. The mean number of oocytes obtained was 23.4 ± 15.4, of which 83% were mature (metaphase II). None of the patients developed any signs or symptoms of OHSS. So far, four clinical pregnancies have been achieved from the embryos obtained during these cycles, including the first birth following this approach. It is concluded that GnRH agonist effectively triggers an endogenous LH surge for final oocyte maturation after ganirelix treatment in stimulated cycles. Our preliminary results suggest that this regimen may prove effective in triggering ovulation and could be said to prevent OHSS in high responders. The efficacy and safety of such new treatment regimen needs to be established in comparative randomized studies.
Key words: GnRH agonist/GnRH antagonist/ovarian hyperstimulation syndrome/recombinant FSH/triggering ovulation
4 To whom correspondence should be addressed at: Department of Obstetrics and Gynecology, Rambam Medical Center, POB 9602, Haifa, Israel 31096. E mail: Itskovitz{at}rambam.health.gov.il
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Griesinger, S. von Otte, A. Schroer, A.K. Ludwig, K. Diedrich, S. Al-Hasani, and A. Schultze-Mosgau Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study Hum. Reprod., May 1, 2007; 22(5): 1348 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. F. VLAHOS and O. GREGORIOU Prevention and Management of Ovarian Hyperstimulation Syndrome Ann. N.Y. Acad. Sci., December 1, 2006; 1092(1): 247 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kol Agonist trigger in the context of OHSS prevention: primum non nocere Hum. Reprod. Update, May 1, 2006; 12(3): 327 - 328. [Full Text] [PDF]
|
|
|
|
|
|
G. Griesinger, K. Diedrich, P. Devroey, and E.M. Kolibianakis Reply: Agonist trigger in the context of OHSS prevention: primum non nocere Hum. Reprod. Update, May 1, 2006; 12(3): 328 - 329. [Full Text] [PDF]
|
|
|
|
|
|
R. Babayof, E. J. Margalioth, M. Huleihel, A. Amash, E. Zylber-Haran, M. Gal, B. Brooks, T. Mimoni, and T. Eldar-Geva Serum inhibin A, VEGF and TNF{alpha} levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial Hum. Reprod., May 1, 2006; 21(5): 1260 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Griesinger, K. Diedrich, P. Devroey, and E.M. Kolibianakis GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis Hum. Reprod. Update, March 1, 2006; 12(2): 159 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Engmann and C. Benadiva GnRH agonist (buserelin) or HCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study Hum. Reprod., November 1, 2005; 20(11): 3258 - 3260. [Full Text] [PDF]
|
|
|
|
|
|
E.M. Kolibianakis, A. Schultze-Mosgau, A. Schroer, A. van Steirteghem, P. Devroey, K. Diedrich, and G. Griesinger A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists Hum. Reprod., October 1, 2005; 20(10): 2887 - 2892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kol Prediction of ovarian hyperstimulation syndrome: why predict if we can prevent! Hum. Reprod., July 1, 2003; 18(7): 1557 - 1558. [Full Text] [PDF]
|
|
|
|
|
|
Z.O. Amarin Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome: An aggressive, but perhaps life-saving procedure Hum. Reprod., April 1, 2003; 18(4): 659 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Herbst, B. D. Anawalt, J. K. Amory, and W. J. Bremner Acyline: The First Study in Humans of a Potent, New Gonadotropin-Releasing Hormone Antagonist J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3215 - 3220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Fauser, D. de Jong, F. Olivennes, H. Wramsby, C. Tay, J. Itskovitz-Eldor, and H. G. van Hooren Endocrine Profiles after Triggering of Final Oocyte Maturation with GnRH Agonist after Cotreatment with the GnRH Antagonist Ganirelix during Ovarian Hyperstimulation for in Vitro Fertilization J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 709 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. European Middle East Orgalutran Study Group* Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation Hum. Reprod., April 1, 2001; 16(4): 644 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kol and O.-S. Tang Should we explore OHSS full clinical scope?... Hum. Reprod., March 1, 2001; 16(3): 595 - 596. [Full Text] [PDF]
|
|